Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications

Molecular Medicine Today

Volumn 4, Issue 2, 1998, Pages 63-68

  Strand, S ^a   Galle, P R ^a  

^a Dept of Internal Medicine ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; CANCER CELL; CANCER IMMUNOLOGY; CELL DEATH; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALIA;

EID: 0031932868     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)01191-X     Document Type: Article

References (46)

1. Chen H.L. Carbone D.P. p53 as target for anti-cancer immunotherapy Mol. Med. Today 3 1997 160 167
2. Hakansson A. Gustafsson B. Krysander L. Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment Br. J. Cancer 7 1996 670 676
3. Schreiber H. Tumor immunology Paul W.E. Fundamental Immunology 3rd edn 1991 Raven Press Washington, DC 1143 1174
4. Matis L.A. The molecular basis of T-cell specificity Annu. Rev. Immunol. 8 1990 65 82
5. Lenschow D.J. Walunas T.L. Bluestone J.A. CD28/B7 system of T cell co-stimulation Annu. Rev. Immunol. 14 1996 233 258
6. Nagata S. Apoptosis by death factor Cell 88 1997 355 365
7. Peter, M.E. et al. The death receptors , in Apoptosis: Biology, Mechanisms and Role in Disease (Kumara, S., ed.), Springer-Verlag (in press)
8. Galle P.R. Involvement of the APO-1/Fas (CD95) receptor and ligand in liver damage J. Exp. Med. 182 1995 1223 1230
9. Darmon A.J. Nicholson D.W. Bleakley R.C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B Nature 377 1995 446 448
10. Froelich C.J. New paradigm for lymphocyte granule-mediated cytotoxicity J. Biol. Chem. 271 1996 29073 29079
11. Russel J.H. Rush B. Weaver C. Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide Proc. Natl. Acad. Sci. U. S.A. 90 1993 4409 4413
12. Singer G.G. Abbas A.K. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice Immunity 1 1994 365 371
13. Kaklamanis L. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastasic versus primary breast cancer Cancer Res. 55 1995 5191 5194
14. Hathcock K. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function J. Exp. Med. 180 1994 631 640
15. Musiani P. Cytokines, tumour-cell death and immunogenicity: a question of choice Immunol. Today 18 1997 32 36
16. Harding F.A. CD-28 mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature 365 1992 607 609
17. Williams, K.A. and Coster, D.J. Rethinking immunological privilege: implications for corneal and limbal stem cell transplantation , Mol. Med. Today (in press)
18. Streilein J.W. Tissue barriers, immunosuppressive microenvironments, and privileged sites: the eye's point of view Reg. Immunol. 5 1993 253 268
19. Griffith T.S. Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1995 1189 1192
20. Bellgrau D. A role for CD95 ligand in preventing graft rejection Nature 377 1995 630 632
21. Yagita H. Seino K.I. Kayagaki N. Okumura K. CD95 ligand in graft rejection Nature 378 1996 682
22. Tisch R. McDevitt H. Insulin-dependent diabetes mellitus Cell 85 1996 291 297
23. Lau H.T. Yu M. Fontana A. Stoeckert C.J. Jr Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice Science 273 1996 109 112
24. Chevronsky A.V. The role of Fas in autoimmune diabetes Cell 89 1997 17 24
25. Kang S-M. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction Nat. Med. 3 1997 738 743
26. Leithäuser F. Constitutive and induced expression of APO-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells Lab. Invest. 69 1993 415 429
27. Strand S. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells — a mechanism of immune evasion? Nat. Med. 2 1996 1361 1367
28. Owen-Schaub L.B. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 94 1995 1 8
29. Bates S. Vousden K.H. p53 in signalling checkpoint arrest or apoptosis Curr. Opin. Genet. Dev. 6 1996 12 19
30. Lane D.P. p53, guardian of the genome Nature 358 1992 15 16
31. Owen-Schaub L.B. Wild-type human p53 and a temperature-sensitive mutant induce FAS/APO-1 expression Mol. Cell Biol. 15 1995 3032 3040
32. Müller M. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of p53 J. Clin. Invest. 99 1997 403 413
33. Itoh N. S. Nagata Effect of Bcl-2 on Fas antigen-mediated cell death J. Immunol. 151 1993 621 627
34. Rodriguez I. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection J. Exp. Med. 183 1996 1031 1036
35. Coustan-Smith E. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia Blood 87 1996 1140 1146
36. Ilyas M. Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative-colitis-associated carcinomas Am. J. Pathol. 149 1996 1719 1726
37. Yang E. Korsmeyer S.J. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death Blood 88 1996 386 401
38. Weller M. Protooncogene bcl-2 gene transfer abrogates Fas/APO- 1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation J. Clin. Invest. 95 1995 2633 2643
39. Jaattela M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells Oncogene 10 1995 2297 2305
40. Bargou R.C. Overexpression of the death-promoting gene bax-a which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces growth in scid mice J. Clin. Invest. 97 1996 2651 2659
41. Sun L-X. Teshigawara K. Uchida A. Bcl-2 inhibits B7-induced MHC-unrestricted cytolysis mediated by a human NK cell line Immunol. Invest. 25 1996 307 319
42. O'Connell J. O'Sullivan G.C. Collins J.K. Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J. Exp. Med. 184 1996 1075 1082
43. Hahne M. Melanoma cell expression of Fas (APO-1/CD95) ligand — implications for tumor immune escape Science 274 1996 1363 1366
44. Saas P. Fas ligand expression by astrocytoma in vivo : maintaining immune privilege in the brain? J. Clin. Invest. 99 1997 1173 1178
45. Niehans G.A. Human lung cancer cells express Fas ligand Cancer Res. 57 1997 1007 1012
46. Thome M. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors Nature 386 1997 517 521